	US 12,404,339 B2
	Method of depleting target antigen-specific antibody from a patient by administering a fusion protein (Seldeg) for selectively depleting antigen-specific antibodies
Elizabeth Sally Ward Ober, Southampton (GB); Venkata Siva Charan Devanaboyina, College Station, TX (US); and Raimund Johannes Ober, Southampton (GB)
Assigned to The Texas A&M University System, College Station, TX (US)
Filed by THE TEXAS A&M UNIVERSITY SYSTEM, College Station, TX (US)
Filed on Sep. 8, 2022, as Appl. No. 17/930,545.
Application 17/930,545 is a continuation of application No. 16/465,975, granted, now 11,459,396, previously published as PCT/US2017/064186, filed on Dec. 1, 2017.
Claims priority of provisional application 62/429,367, filed on Dec. 2, 2016.
Prior Publication US 2023/0087965 A1, Mar. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); C07K 14/71 (2006.01); A61K 51/10 (2006.01)

CPC C07K 16/2881 (2013.01) [A61K 39/00 (2013.01); A61K 39/0011 (2013.01); C07K 14/71 (2013.01); A61K 38/00 (2013.01); A61K 51/1027 (2013.01); C07K 2317/52 (2013.01); C07K 2317/569 (2013.01); C07K 2317/71 (2013.01); C07K 2317/72 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01)]

18 Claims

1. A method of depleting target antigen-specific antibody from a patient, the method comprising:

administering to the patient a Seldeg in an amount sufficient to remove at least 50% of the target antigen-specific antibody from a circulation or a target tissue in the patient,

wherein the Seldeg comprises

a targeting component having a protein or a protein fragment configured to specifically bind to an internalizing cell surface receptor or internalizing surface molecule; and

an antigen component, having one molecule of an antigen, an antigen fragment or an antigen mimetic configured to specifically bind a target antigen-specific antibody or a variant thereof;

wherein the targeting protein component is fused directly or indirectly to the antigen component.